

Table 8: Analysis of NIHSS Score and Change From Baseline Using a Repeated Measures Mixed Effects Model in the Modified Intent-to-Treat (MITT) Population

Analysis of NIHSS score and change from baseline using a repeated measures mixed effects model in the Modified-Intent-to-Treat (MITT) population

	Adjusted mean change from baseline (Natalizumab vs placebo)	Two-sided 90% confidence interval	One sided p-value
24 Hours	-0.25	[-2.48, 1.98]	0.427
Day 5	1.71	[-0.52, 3.94]	0.896
Day 30	3.15	[0.89, 5.40]	0.989
Day 90/Final Vst	1.93	[-0.38, 4.25]	0.915

Note 1: The MITT population is defined as all subjects who were randomized and have received the entire infusion of study treatment.

2: The repeated measures mixed effects model is modeling absolute change in NIHSS score relative to baseline and using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, baseline NIHSS score and location of stroke.